Tonix Pharmaceuticals Holding Corp. TNXP announced the successful completion of its public offering. Following the announcement, the biopharmaceutical company’s shares soared, trading 22.94% higher in the pre-market on Friday.
What Happened: The public offering included 1,199,448 shares of common stock and pre-funded warrants to purchase up to 2,568,110 shares of common stock. The shares and warrants were priced at $1.065 and $1.064 respectively, with the warrants having an exercise price of $0.001 per share.
At the time of writing, it was trading at $1.34, according to Benzinga Pro.
The gross proceeds from the offering amounted to $4 million, before deducting placement agent fees and other estimated offering expenses. Tonix Pharmaceuticals plans to use the net proceeds for working capital and general corporate purposes, including the preparation of the new drug application for its Tonmya product candidate in patients with fibromyalgia, and to pay off a portion of its existing debt.
Dawson James Securities, Inc. served as the sole placement agent for the offering. Legal representation was provided by Lowenstein Sandler, New York, NY for the company, and ArentFox Schiff LLP, Washington, DC for the placement agent.
The offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with the U.S. Securities and Exchange Commission (the "SEC").
U.S. stocks settled mixed on Thursday, with the S&P 500 recording a fourth consecutive closing record. On the economic data front, U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain following a 0.5% increase in April. U.S. initial jobless claims rose by 13,000 to 242,000 in the week ending June 8, compared to market estimates of 225,000.
Read Next: Bee Vectoring Technology Helps Crops Grow; Partnerships Help BVT Grow
Image via Shutterstock
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
